Table 1.
Genetic mutations of LA, PDTC, and ATC.
| LA | PDTC | ATC | |
|---|---|---|---|
| EGFR* | 14% | / | / |
| ALK* | / | 4% | / |
| RET* | / | 6% | / |
| MET | 7% | / | / |
| nRAS* | / | 21% | 18% |
| hRAS | / | 5% | 6% |
| kRAS* | 33% | 2% | / |
| BRAF* | 10% | 33% | 45% |
| PIK3CA* | 7% | 2% | 18% |
| pTEN | / | 4% | 15% |
| EIF1AX | / | 11% | 9% |
| TERT* | / | 40% | 73% |
| NF1 | 11% | / | 9% |
| TSH-R | / | 2% | 6% |
| STK11 | 17% | 1% | 6% |
| PAx8/PPAR gamma | / | 4% | / |
| TP53 | 46% | 8% | 73% |
| ATM | / | 7% | 9% |
| RB1 | 4% | 1% | 9% |
| PI3K/AKT | / | 11% | 39% |
| SWI/SNF | / | 6% | 36% |
| HMTs | / | 7% | 24% |
| MMR | / | 2% | 12% |
| KEAP1 | 17% | / | / |
LA, Lung Adenocarcinoma; PDTC, Poorly Differentiated Thyroid Carcinoma; ATC, Anaplastic Thyroid Carcinoma;
Genes analyzed in our samples after DNA extraction with MALDI-TOF mass spectrometry [EGFR (Exon 18, mutation and deletion of codon 709 and 719; Exon 19, mutation and deletion of codon 744–759; Exon 20, mutation and insertion of codon 767–775 and 790; Exon 21, mutation of codon 833, 835, 848, 854, 858, and 861); kRAS (Mutation codon 12, 13, 61); nRAS (Mutation in codon 12 and 61); BRAF (Mutation in codon 466, 469, 594, 597, 600); PIK3CA (Mutation in codon 542, 545, 1,043, 1,047); ALK (Mutation in codon 1,156, 1,196, 1,269); ERBB2 (Mutation in exon 20); DDR2 (Mutation in codon 239, 638, 768); MAP2K1 (Mutation in codon 56, 57, 67); RET (Mutation in codon 918); TERT (Mutation C228T)].